HOME >> BIOLOGY >> NEWS
Introgens gene drug demonstrates tumor growth control

Results of human melanoma studies published in International Journal Of Cancer

Houston and Austin, TX, October 25, 2001- Introgen Therapeutics, Inc. (NASDAQ: INGN) announced today that results of preclinical studies in melanoma have been published in the October 2001 issue of International Journal of Cancer in a manuscript entitled Down-Regulated Melanoma Differentiation Associated Gene (MDA-7) Expression in Human Melanomas. The manuscripts authors include lead author Dr. Suhendan Ekmekcioglu, Instructor in the Department of Bioimmunotherapy at M. D. Anderson Cancer Center, Dr. Elizabeth Grimm, Ashbel Smith Professor in the Departments of Bioimmunotherapy and Surgical Oncology at M. D. Anderson Cancer Center, Dr. Sunil Chada, Introgens director of research and development, and Dr. Abner Mhashilkar, project leader of Introgens INGN 241 (Adenoviral-mda7) program. The published studies were designed to answer two important questions in understanding the role of the mda-7 gene in skin cancer. First, how MDA-7 protein is regulated as tumors develop from benign moles to the full-blown skin cancer known as melanoma and secondly, how over-expression of the mda-7 gene will affect melanoma cancer cell growth.

In the scientific publication, the researchers conclude that the MDA-7 protein is present in normal melanocytes (cells responsible for pigmentation in the skin) and early stages of melanoma tumors. However, as the cancer advances, the MDA-7 protein is lost. In the highly aggressive metastatic disease, MDA-7 protein is virtually non-existent. This study demonstrates that mda-7 is a key tumor suppressor gene whose function is lost as melanoma tumors grow more aggressively.

INGN 241 is a modified adenoviral vector that carries the cancer cell killing mda-7 gene. Previous studies indicated that Adenoviral-mda7 treatment results in targeted destruction of breast, lung and colon cancer cells, while sparing normal cells. A Phase I clinica
'"/>

Contact: Channing Burke
c.burke@introgen.com
512-708-9310
Porter Novelli
25-Oct-2001


Page: 1 2 3 4

Related biology news :

1. New genetic research demonstrates possible cause of inherited form of Parkinsons disease
2. Study demonstrates altered angiogenic proteins in preeclampsia patients
3. New study demonstrates bone protein can reverse kidney failure
4. Study demonstrates that low dose tamoxifen may be effective in treating breast cancer
5. Animal study demonstrates carbon monoxide may help heart patients
6. Binary enzyme created by TSRI scientists demonstrates Darwinian evolution at its simplest
7. New UGA study demonstrates bacterial pathogens use hydrogen as energy source in animals
8. Inhibitor of novel cancer target, LPAAT-beta, demonstrates selective anti-cancer effects
9. Norwegian study demonstrates targeted coxibs may prevent oral cancer
10. New physical activity opinion survey demonstrates perceptions do not meet reality
11. Testosterone gel (AndroGel) study demonstrates safety and efficacy up to 42 months

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/23/2020)... ... June 23, 2020 , ... ... pleased to announce the next event in a series of TOPIQ webinars, which ... TOPIQ series of webinars was developed in response to social distancing measures that ...
(Date:6/13/2020)... ... June 11, 2020 , ... Bode Technology (Bode), ... forensic genealogy team. Bode’s Forensic Genealogy Service (FGS) continues to deliver ... analysis methods. The team has added experienced genealogists, each having over a decade ...
(Date:6/5/2020)... ... June 04, 2020 , ... Greffex, a pioneering vaccine and gene ... Directors. , “Neil understands the need for a global perspective to make an impact ... Greffex. Mr. Bush will serve as an independent, director of the company. , “The ...
Breaking Biology News(10 mins):
(Date:6/23/2020)... ... June 22, 2020 , ... Dracen Pharmaceuticals Inc., announced ... June 22-24 during the American Association for Cancer Research Virtual meeting. One poster ... potent, consistent single agent activity in KEAP1 mutant tumor models of NSCLC. ...
(Date:6/11/2020)... ... June 08, 2020 , ... Greffex, a leading ... use of proprietary clean viral vectors, recently announced a key manufacturing agreement with ... platform is the world’s most successful gene therapy delivery vehicle (vector) with broad ...
(Date:6/11/2020)... ... June 09, 2020 , ... Reducing carbon emissions has been ... the Paris Agreement to stock market dips, ways to reduce CO2 is something we ... their portfolio. Most of the biofuels being produced today are created from recycled cooking ...
(Date:5/30/2020)... ... May 29, 2020 , ... Medrio, Inc., the leading ... markets, has enabled Cytovale, Inc., a medical technology company dedicated to revolutionizing diagnostics ... their first patient in (FPI) in just seven days. The Cytovale technology will ...
Breaking Biology Technology:
Cached News: